Stockreport

Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk [Yahoo! Finance]

Adagene Inc. - ADS, each representing 1.25 ordinary shares  (ADAG) 
PDF The company is developing ADG126 as a “masked” anti-CTLA-4 antibody intended to improve the safety of CTLA-4 blockade while enabling higher dosing in combination regimen [Read more]